←
BioSpace38,553 posts
BioSpace avatar

BioSpace

@biospace

Your source for biopharma news and jobs

◷ Joined February 2009▧ 7,081 Photos and videos
BioSpace avatar
BioSpace@biospace·21h

Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals. hubs.li/Q04FwvVr0

BioSpace avatar
BioSpace@biospace·21h

At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease. hubs.li/Q04Fv_gF0

BioSpace avatar
BioSpace@biospace·22h

Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia. hubs.li/Q04FvR120

BioSpace avatar
BioSpace@biospace·23h

It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million. hubs.li/Q04FtYMD0

BioSpace avatar
BioSpace@biospace·Nov 16

Helus Pharma’s psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events. hubs.li/Q04FmGJ60

BioSpace avatar
BioSpace@biospace·Nov 16

Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setbacks. hubs.li/Q04Fnrzj0

BioSpace avatar
BioSpace@biospace·Nov 16

The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie. hubs.li/Q04Fns0-0

BioSpace avatar
BioSpace@biospace·Nov 16

As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago. hubs.ly/Q04Fm2vQ0